220 related articles for article (PubMed ID: 36937443)
21. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.
Xu X; Yu Y; Liu M; Liang L; Liu T
Transl Cancer Res; 2022 Jan; 11(1):276-287. PubMed ID: 35261903
[TBL] [Abstract][Full Text] [Related]
22. Third-line treatment options in metastatic pancreatic cancer patients: a real-world study.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Front Oncol; 2023; 13():1251258. PubMed ID: 37810973
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital.
Yuan M; Wang Z; Zhao Y; Feng T; Lv W; Zhong H
Front Pharmacol; 2021; 12():632076. PubMed ID: 34122063
[TBL] [Abstract][Full Text] [Related]
24. Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
Cheng Y; Du FC; Fang FQ; Duan ZJ; Lei W; Shi KG
Neoplasma; 2020 Nov; 67(6):1384-1390. PubMed ID: 32657613
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of raltitrexed plus S-1
Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer.
Sun L; Huang S; Li D; Mao Y; Wang Y; Wu J
Front Oncol; 2021; 11():754881. PubMed ID: 34692541
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer.
Zou J; Wang Y; Xu J; Li J; Wang T; Zhang Y; Bai Y
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202064
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study.
Wang RT; Zhao Y; Wang AL; Wang YT; Yin ZP; Chen K
Int J Gen Med; 2021; 14():5363-5373. PubMed ID: 34522132
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
Ding X; Liu Y; Zhang Y; Liang J; Li Q; Hu H; Zhou Y
Anticancer Drugs; 2023 Aug; 34(7):877-882. PubMed ID: 36539356
[TBL] [Abstract][Full Text] [Related]
33. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215).
Zhao W; Lei J; Ke S; Chen Y; Xiao J; Tang Z; Wang L; Ren Y; Alnaggar M; Qiu H; Shi W; Yin L; Chen Y
EClinicalMedicine; 2023 Dec; 66():102315. PubMed ID: 38024475
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
35. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
36. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China.
Peng W; Zhang F; Wang Z; Li D; He Y; Ning Z; Sheng L; Wang J; Xia X; Yu C; Wang Z; Zhao Y; Liang H; Hu B; Sun C; Wang D; Cheng Y; Pan M; Xia L; Guo X; Zhang Y; Hu Z; Li X; Lu L; Zhang J; Qian H; Xie H; Sun G
Cancer Manag Res; 2020; 12():6977-6985. PubMed ID: 32821164
[TBL] [Abstract][Full Text] [Related]
37. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
Front Oncol; 2020; 10():587692. PubMed ID: 33282739
[TBL] [Abstract][Full Text] [Related]
38. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
[TBL] [Abstract][Full Text] [Related]
39. Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C; De Stefano A; Rosati G; Cassata A; Silvestro L; Borrelli M; Di Gennaro E; Romano C; Nappi A; Zanaletti N; Foschini F; Casaretti R; Tatangelo F; Lastoria S; Raddi M; Bilancia D; Granata V; Setola S; Petrillo A; Vitagliano C; Gargiulo P; Arenare L; Febbraro A; Martinelli E; Ciardiello F; Delrio P; Budillon A; Piccirillo MC; Avallone A
ESMO Open; 2023 Feb; 8(1):100748. PubMed ID: 36603521
[TBL] [Abstract][Full Text] [Related]
40. Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.
Wan Y; Luo D
J Gastrointest Oncol; 2023 Feb; 14(1):450-457. PubMed ID: 36915460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
